Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I.

Published

Journal Article

INTRODUCTION: The aim of this study was to determine the safety and therapeutic potential of L-carnitine and valproic acid (VPA) in infants with spinal muscular atrophy (SMA). METHODS: Our investigation was an open-label phase 2 multicenter trial of L-carnitine and VPA in infants with SMA type I with retrospective comparison to an untreated, matched cohort. Primary outcomes were: safety and adverse events; secondary outcomes were survival, time to death/>16 hours/day of ventilator support; motor outcomes; and maximum ulnar compound motor action potential amplitude. RESULTS: A total of 245 AEs were observed in 35 of the 37 treated subjects (95%). Respiratory events accounted for 49% of all adverse events, resulting in 14 deaths. Survival was not significantly different between treated and untreated cohorts. DISCUSSION: This trial provides evidence that, in infants with SMA type I, L-carnitine/VPA is ineffective at altering survival. The substantial proportion of infants reaching end-points within 6 months of enrollment underscores the urgent need for pre-symptomatic treatment in SMA type I. Muscle Nerve 57: 193-199, 2018.

Full Text

Duke Authors

Cited Authors

  • Krosschell, KJ; Kissel, JT; Townsend, EL; Simeone, SD; Zhang, RZ; Reyna, SP; Crawford, TO; Schroth, MK; Acsadi, G; Kishnani, PS; Von Kleist-Retzow, J-C; Hero, B; D'Anjou, G; Smith, EC; Elsheikh, B; Simard, LR; Prior, TW; Scott, CB; Lasalle, B; Sakonju, A; Wirth, B; Swoboda, KJ; Project Cure SMA Investigator's Network,

Published Date

  • February 2018

Published In

Volume / Issue

  • 57 / 2

Start / End Page

  • 193 - 199

PubMed ID

  • 28833236

Pubmed Central ID

  • 28833236

Electronic International Standard Serial Number (EISSN)

  • 1097-4598

Digital Object Identifier (DOI)

  • 10.1002/mus.25776

Language

  • eng

Conference Location

  • United States